FindTrial
Sign In

TAK-788

DRUG7 trials

Sponsors

Takeda, Millennium Pharmaceuticals, Inc.

Conditions

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small-Cell LungHealthy VolunteersLung NeoplasmsNon-Small Cell Lung Cancer (NSCLC)

Phase 1

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
Active, not recruitingNCT02716116
TakedaCarcinoma, Non-Small-Cell Lung
Start: 2016-06-16End: 2026-10-31Target: 334Updated: 2026-02-25
A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants
CompletedNCT03482453
Millennium Pharmaceuticals, Inc.Healthy Volunteers
Start: 2018-03-28End: 2019-01-18Updated: 2020-01-29
A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants
CompletedNCT03928327
Millennium Pharmaceuticals, Inc.Healthy Volunteers
Start: 2019-05-02End: 2019-08-16Updated: 2020-08-21
Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
CompletedNCT04051827
Millennium Pharmaceuticals, Inc.Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Start: 2019-12-23End: 2021-12-07Updated: 2025-07-28
A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult Participants
CompletedNCT04441255
TakedaHealthy Volunteers
Start: 2020-07-01End: 2020-08-10Updated: 2021-09-05

Phase 2

A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788
WithdrawnNCT04576208
TakedaNon-Small Cell Lung Cancer (NSCLC)
Start: 2020-11-30End: 2022-07-31Updated: 2020-12-17

Phase 3

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
Active, not recruitingNCT04129502
TakedaAdvanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Start: 2020-01-10End: 2026-10-31Updated: 2026-03-30

Related Papers

Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity.
2025-09-24
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
Journal of Clinical Oncology2025-01-2916 citations
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [<sup>14</sup>C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants.
2024-05-245 citations
Mobocertinib: Mechanism of action, clinical, and translational science
Clinical and Translational Science2024-03-0116 citations
Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.
2023-12-043 citations
Abstract B153: Resistance mechanisms to mobocertinib in treating NSCLC with <i>EGFR</i> exon 20 insertion mutations
Molecular Cancer Therapeutics2023-12-011 citations
Matching-Adjusted Indirect Comparison of Amivantamab vs Mobocertinib in Platinum-Pretreated <i>EGFR</i> Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer
Future Oncology2023-10-261 citations
Real-World Response and Outcomes in Patients With NSCLC With <i>EGFR</i> Exon 20 Insertion Mutations.
2023-08-1641 citations
Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials
Experimental Hematology and Oncology2023-06-097 citations
Mobocertinib efficacy in patients with NSCLC and <i>EGFR</i> exon 20 insertion mutations (ex20ins) identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA).
Journal of Clinical Oncology2023-06-011 citations
Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations.
2023-04-085 citations
Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
2023-04-015 citations
Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC.
2023-02-0345 citations
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
Journal of Clinical Medicine2022-12-2313 citations
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for <i>EGFR</i> exon 20 insertion–positive non–small cell lung cancer
Expert Review of Anticancer Therapy2022-12-209 citations
FDA Approval Summary: Mobocertinib for Metastatic Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations
Clinical Cancer Research2022-09-1636 citations
Abstract 2781: De novo molecular mechanisms of resistance to mobocertinib
Cancer Research2022-06-153 citations
Mobocertinib (TAK-788) in <i>EGFR</i> exon 20 insertion (ex20ins)+ metastatic non–small cell lung cancer (mNSCLC): Treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD.
Journal of Clinical Oncology2022-06-017 citations
Matching-adjusted indirect comparison (MAIC) of mobocertinib versus amivantamab in patients with non–small cell lung cancer (NSCLC) with <i>EGFR</i> exon 20 insertions (ex20ins).
Journal of Clinical Oncology2022-06-013 citations
Molecular analysis of circulating tumor DNA (ctDNA) in patients (pts) with <i>EGFR </i>exon 20 insertion-positive (ex20ins+) advanced NSCLC treated with mobocertinib.
Journal of Clinical Oncology2022-06-013 citations

11 more papers not shown